CON · Concentra Group Holdings Parent, Inc.
$34.42
-0.92 (-2.60%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$4.50B
Shares
127.52M
Volume · Sep 30
1.09M
Avg daily vol (3M)
933.52K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$34.42
Open$35.39
Day$34.39–35.42
52W close$18.71–36.37
Avg vol 30d875K
Short int3.2M · 2.5% float · 4.5d
Short vol50%
Last earningsAug 7, 2026
DataJul 2024–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.29B
Trailing 12 months
Net income (TTM)
$198.73M
Trailing 12 months
Revenue growth YoY
+10.0%
Year over year
Operating margin
16.4%
Trailing 12 months
P / E (TTM)
22.8
Trailing earnings · reciprocal yield 4.4%
FCF yield
5.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$158.04M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.3%
Year over year · fewer shares
Price change (1Y)
+70.2%
Trailing year
Short interest
2.5%
Latest settlement · 4.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Low
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+30%
above
Price vs 50-day avg
+1%
above
RSI (14)
48
neutral
MACD trend
Negative
52-week position
89%
near high
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+55%
trailing
YTD return
+75%
this year
Relative strength
+43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $34 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +54 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.50% of float · ▲ +13.6% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
292 holders — near 2-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+14%
Y/Y
EPS growth
−11%
Y/Y
Free cash flow
$197.1M
Valuation
P/E 22.8
in line
Buyback
$54.1M
remaining
Quant / Vol
risk profile
Volatility
28%
annualized · 1-yr
Max drawdown
−14%
past year
ATR
2.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Revenue
· full year 2026
Initiated
$2.33B – $2.38B
prior FY $2.16B
midpoint +8.6% Y/Y
Adjusted EBITDA
· full year 2026
Non-GAAP
Initiated
$485M – $495M
Capital expenditures
· full year 2026
Initiated
$70M – $80M
Free Cash Flow
· full year 2026
Non-GAAP
Initiated
$220M – $240M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+30%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
89%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $34 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +54 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.50% of float · ▲ +13.6% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
292 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $19
Now $34 · 89%
Range high $36
vs 200-day avg +30%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Earnings per Share non-GAAP | $0.52 | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Earnings per share on a fully diluted basis $0.51
+$0 Loss on early retirement of debt
+$0.01 Separation transaction costs
+$0 Nova and Pivot Onsite Innovations acquisition costs
+$0 Less: tax effect of adjustments
= Adjusted Earnings per Share $0.52
|
|||
| Adjusted EBITDA non-GAAP | $140.93M | Three Months Ended June 30, 2026 filing | — |
| Adjusted Net Income Attributable to the Company non-GAAP | $66.68M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net income attributable to the Company 65.3M
+0K Loss on early retirement of debt
+1.78M Separation transaction costs
+60K Nova and Pivot Onsite Innovations acquisition costs
-454K Less: tax effect of adjustments
= Adjusted Net Income Attributable to the Company 66.68M
|
|||
| Consumer health patient visits | 50,967 | Three Months Ended June 30, 2026 filing | — |
| Consumer health revenue per visit | $135.26 | Three Months Ended June 30, 2026 filing | — |
| Consumer health VPD volume | 796 | Three Months Ended June 30, 2026 filing | — |
| Employer services patient visits | 1,910,984 | Three Months Ended June 30, 2026 filing | — |
| Employer services revenue per visit | $95.84 | Three Months Ended June 30, 2026 filing | — |
| Employer services VPD volume | 29,859 | Three Months Ended June 30, 2026 filing | — |
| Free Cash Flow non-GAAP | $121.01M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 135.21M
-14.2M Net cash used in investing activities
+0K Business combinations, net of cash acquired
= Free Cash Flow 121.01M
|
|||
| Number of occupational health centers—end of period | 633 | Three Months Ended June 30, 2026 filing | — |
| Number of onsite health clinics—end of period | 415 | Three Months Ended June 30, 2026 filing | — |
| Revenue per visit | $152.67 | Three Months Ended June 30, 2026 filing | — |
| Segment Adjusted EBITDA non-GAAP | $140.93M | Three Months Ended June 30, 2026 filing | — |
| Total patient visits | 3,610,934 | Three Months Ended June 30, 2026 filing | — |
| VPD volume | 56,421 | Three Months Ended June 30, 2026 filing | — |
| Workers' compensation patient visits | 1,648,983 | Three Months Ended June 30, 2026 filing | — |
| Workers' compensation revenue per visit | $219.06 | Three Months Ended June 30, 2026 filing | — |
| Workers' compensation VPD volume | 25,765 | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CON
this stock
Concentra Group Holdings Parent, Inc.
|
$4.50B | +74.9% | +13.9% | 22.8 | 2.5% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -8.6% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -11.6% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +28.6% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$12.18B | +14.5% | +10.5% | 20.1 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CON | -1.1% | +1.6% | +55.1% | +2.0% | +74.9% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -0.4% | +1.5% | +42.9% | +2.6% | +63.1% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$100.00M
Spent (derived)
$45.90M
Remaining
$54.10M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.